

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029047 A1

(51) International Patent Classification⁷: C07D 409/12, 295/08, A61K 31/381, 31/44

(21) International Application Number:
PCT/US2003/026304

(22) International Filing Date:
22 September 2003 (22.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/413,609 25 September 2002 (25.09.2002) US

(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): WALLACE, Owen, Brendan [US/US]; 4341 Chase Circle, Zionsville, IN 46077 (US).

(74) Agents: BOUDREAUX, William, R. et al.; Eli Lilly And Company, P. O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY,

[Continued on next page]

(54) Title: DERIVATIVE OF DIHYDRO-DIBENZO (A) ANTHRACENES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS



(57) Abstract: The present invention provides a compound of the formula (I) wherein R¹ is -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), or -OSO₂(C₂-C₆ alkyl); R⁰, R² and R³ are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₂-C₆ alkyl) or halo; R⁴ is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3; X is S- or -HC=CH-; and Y is O-, -S-, -NH-, -NMe-, or -CH₂-; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof,

optionally in combination with estrogen and progestin; methods of inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.



CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
— of inventorship (Rule 4.17(iv)) for US only

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

DERIVATIVE OF DIHYDRO-DIBENZO (A) ANTHRACENES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS

BACKGROUND OF THE INVENTION

5 The present invention relates to dihydro-dibenzoanthracenes and derivatives thereof, compositions containing those compounds, their use as selective estrogen receptor modulators, and their use in inhibiting bone loss, cardiovascular disease, and breast and uterine carcinoma.

 Menopause, the transition in women from the reproductive to the non-
10 reproductive stage of life, is characterized by the cessation of menstruation and occurs at an average age of fifty years. The postmenopausal state is characterized by changes in the levels of circulating sex hormones, the most dramatic of which is the reduction in plasma levels of 17β -estradiol to less than ten percent of premenopausal values. Clinical and epidemiological studies have shown that the postmenopausal state is an important risk
15 factor for a number of chronic disorders, notably osteoporosis and cardiovascular disease. In view of the fact that the current life span of women is about eighty years, women spend approximately one-third of their lives in the postmenopausal state. This means that the potential for chronic effects of the postmenopausal state on women's health is greater today than at the turn of the century when life expectancy was considerably shorter.

20 Osteoporosis describes a group of diseases which are characterized by the net loss of bone mass per unit volume. The consequence of this loss of bone mass and resulting bone fracture is the failure of the skeleton to provide adequate structural support for the body. The most vulnerable bone tissue to the effects of postmenopausal osteoporosis is the trabecular bone. This tissue is often referred to as spongy or cancellous bone and is
25 particularly concentrated near the ends of the bone (near the joints) and in the vertebrae of the spine. The trabecular tissue is characterized by small osteoid structures which interconnect with each other, as well as the more solid and dense cortical tissue which makes up the outer surface and central shaft of the bone. This inter-connected network of trabeculae gives lateral support to the outer cortical structure and is critical to the
30 biomechanical strength of the overall structure.

 Following the cessation of menses, most women lose from about 20% to about 60% of the bone mass in the trabecular compartment of the bone within 3 to 6 years. This

rapid loss is generally associated with an increase of bone resorption and formation. However, the resorptive cycle is more dominant and the result is a net loss of bone mass.

In postmenopausal osteoporosis, it is primarily the net resorption and loss of the trabeculae which leads to the failure and fracture of bone. In light of the loss of the
5 trabeculae in postmenopausal women, it is not surprising that the most common fractures are those associated with bones which are highly dependent on trabecular support, for example the vertebrae, the neck, and the weight bearing bones such as the femur and the fore-arm. Indeed, hip fracture, collicles fractures, and vertebral crush fractures are hallmarks of postmenopausal osteoporosis.

10 There are an estimated 25 million women in the United States alone who are afflicted with this disease. The results of osteoporosis are personally harmful and also account for a large economic loss due its chronicity and the need for extensive and long term support (hospitalization and nursing home care). This is especially true in more elderly patients. Additionally, although osteoporosis is not generally thought of as a life
15 threatening condition, a 20% to 30% mortality rate is related with hip fractures in elderly women. A large percentage of this mortality rate can be directly associated with postmenopausal osteoporosis.

Cardiovascular disease is the leading cause of death among women. Compared to men, premenopausal women are relatively protected from cardiovascular disease;
20 however, this protection is gradually lost following menopause. The nature of estrogen's ability to regulate serum lipids is not well understood, but evidence indicates that estrogen can up-regulate the low density lipid (LDL) receptors in the liver which act to remove excess cholesterol. Additionally, estrogen appears to have some effect on the biosynthesis of cholesterol, and other beneficial effects on cardiovascular health.

25 At the present time, one generally accepted method for treatment of disorders resulting in the postmenopausal state from the decline in estrogen levels is estrogen replacement therapy. The therapy may take the form of administering estrogen alone in so-called unopposed estrogen replacement therapy (ERT) or in the form of coadministering estrogen and progestin in a so-called hormonal replacement therapy
30 (HRT) regimen. There are, however, major liabilities associated with chronic administration of estrogen in postmenopausal women having to do with adverse effects on the breast and uterus. Women on ERT develop endometrial cancer at rates three to six

times higher than nonusers after three to six years of use; after ten years of ERT, the risk ratio increases to tenfold.


To combat these deleterious effect of ERT, the coadministration of progestin along with estrogen in a combined hormonal replacement therapy (HRT) is employed,
5 since progestin acts to limit uterine stimulation and thus reduce the risk of uterine cancer.

Because of these known and suspected or feared liabilities of estrogen therapy, prescription of and patient compliance with chronic estrogen replacement therapy has been poor. It has been estimated that, in the United States among postmenopausal women for whom ERT or HRT has been prescribed, fewer than forty percent continue therapy
10 beyond one year.

As a consequence, there is a need for the development of postmenopausal therapy agents which possess the ideal pharmacological profile: for example agents which produce the beneficial effects of estrogen upon skeletal tissue and the cardiovascular system without producing the adverse effects of estrogen upon the breast and the uterus.
15 Agents possessing such an estrogen profile would reverse the effects of estrogen deficiency in certain tissues while at the same time bypassing or failing to act in tissues in which estrogen produces adverse effects. The term selective estrogen receptor modulators or "SERMs" has been applied such compounds which possess this tissue selective profile. SERMs are defined as compounds producing estrogen agonism in one or more desired
20 target tissues such as bone, liver, etc., together with estrogen antagonism and/or minimal (i. e. clinically insignificant) agonism in reproductive tissues such as the breast or uterus.

BRIEF SUMMARY OF THE INVENTION

The present invention provides a compound of the formula



wherein

R^1 is -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), or -OSO₂(C₂-C₆ alkyl);

10 R^0 , R^2 , and R^3 are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₂-C₆ alkyl) or halo;

R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

15 n is 2 or 3;

X is -S- or -HC=CH-; and

Y is -O-, -S-, -NH-, -NMe-, or -CH₂-;

or a pharmaceutically acceptable salt thereof.

20 In a second embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), alone or in combination with estrogen or progestin, and a pharmaceutically acceptable carrier.

25 In a further embodiment, the present invention provides medical methods of employing compounds of the present invention, for alleviating symptoms of estrogen deprivation, including bone loss, for example, osteoporosis; cardiovascular disease, for example hypertension, thrombosis and lowering serum cholesterol.

In an alternative embodiment of the medical method of the present invention, the compounds of the present invention are employed in the treatment of disease conditions associated with an aberrant physiological response to endogenous estrogen including uterine fibroid disease or uterine fibrosis, endometriosis, and estrogen dependent cancers.

5 In a still further embodiment, the invention relates to chemical intermediates used in synthesizing the compounds of Formula (I).

DETAILED DESCRIPTION OF THE INVENTION

General terms used in the description of compounds herein described bear their usual meanings. For example, "C₁-C₆ alkyl" refers to straight, branched, or cyclic
10 aliphatic chains of 1 to 6 carbon atoms including moieties such as methyl, ethyl, propyl, isopropyl, butyl, n-butyl, pentyl, isopentyl, hexyl, isohexyl, cyclohexyl and the like. Likewise, "C₁-C₄ alkyl" refers to straight, branched, or cyclic aliphatic chains of 1 to 4 carbon atoms including moieties such as methyl, ethyl, propyl, isopropyl, butyl, n-butyl,
15 cyclopropyl, and the like. Similarly, the term "C₁-C₄ alkoxy" represents a C₁-C₄ alkyl group attached through an oxygen molecule and include moieties such as, for example, methoxy, ethoxy, n-propoxy, isopropoxy, and the like.

The term "NMe" refers to methylamino. The term "halo" refers to bromo, chloro, fluoro and iodo.

20 As used herein, the term "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures which are not interchangeable. The three-dimensional structures are called configurations. As used herein, the term "enantiomer" refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another. The term "chiral center" refers to a
25 carbon atom to which four different groups are attached. As used herein, the term "diastereomers" refers to stereoisomers which are not enantiomers. In addition, two diastereomers which have a different configuration at only one chiral center are referred to herein as "epimers". The terms "racemate", "racemic mixture" or "racemic modification" refer to a mixture of equal parts of enantiomers.

30

The term "enantiomeric enrichment" as used herein refers to the increase in the amount of one enantiomer as compared to the other. A convenient method of expressing the enantiomeric enrichment achieved is the concept of enantiomeric excess, or "ee", which is found using the following equation:


5


$$ee = \frac{E^1 - E^2}{E^1 + E^2} \times 100$$


wherein E^1 is the amount of the first enantiomer and E^2 is the amount of the second
10 enantiomer. Thus, if the initial ratio of the two enantiomers is 50:50, such as is present in a racemic mixture, and an enantiomeric enrichment sufficient to produce a final ratio of 70:30 is achieved, the ee with respect to the first enantiomer is 40%. However, if the final ratio is 90:10, the ee with respect to the first enantiomer is 80%. An ee of greater than 90% is preferred, an ee of greater than 95% is most preferred and an ee of greater than
15 99% is most especially preferred. Enantiomeric enrichment is readily determined by one of ordinary skill in the art using standard techniques and procedures, such as gas or high performance liquid chromatography with a chiral column. Choice of the appropriate chiral column, eluent and conditions necessary to effect separation of the enantiomeric pair is well within the knowledge of one of ordinary skill in the art. In addition, the
20 specific stereoisomers and enantiomers of compounds of formula I can be prepared by one of ordinary skill in the art utilizing well known techniques and processes, such as those disclosed by J. Jacques, et al., "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc., 1981, and E.L. Eliel and S.H. Wilen, "Stereochemistry of Organic Compounds", (Wiley-Interscience 1994), and European Patent Application No. EP-A-
25 838448, published April 29, 1998. Examples of resolutions include recrystallization techniques or chiral chromatography.

Some of the compounds of the present invention have one or more chiral centers and may exist in a variety of stereoisomeric configurations. As a consequence of these chiral centers, the compounds of the present invention occur as racemates, mixtures of
30 enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. All such racemates, enantiomers, and diastereomers are within the scope of the present invention.

The terms "R" and "S" are used herein as commonly used in organic chemistry to denote specific configuration of a chiral center. The term "R" (rectus) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The term "S" (sinister) refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The priority of groups is based upon their atomic number (in order of decreasing atomic number). A partial list of priorities and a discussion of stereochemistry is contained in "Nomenclature of Organic Compounds: Principles and Practice", (J.H. Fletcher, et al., eds., 1974) at pages 103-120.

The designation "  " refers to a bond that protrudes forward out of the plane of the page.

The designation "  " refers to a bond that protrudes backward out of the plane of the page.

The designation "  " refers to a bond wherein the stereochemistry is not defined.

As used herein, the term "estrogen" includes steroidal compounds having estrogenic activity such as, for example, 17β -estradiol, estrone, conjugated estrogen (Premarin[®]), equine estrogen 17 α -ethynyl estradiol, and the like. As used herein, the term "progestin" includes compounds having progestational activity such as, for example, progesterone, norethynodrel, norgestrel, megestrol acetate, norethindrone, and the like.

Preferred compounds of this invention include compounds of formula I wherein Y is -O-.

Certain R³ and R⁴ groups also demonstrate preferable characteristics. For example, those compounds of formula I wherein R⁴ is 1-pyrrolidinyl, 1-hexamethyleneimino, or 1-piperidinyl are preferred. A further preferred subgroup of the preferred 1-pyrrolidinyl, 1-hexamethyleneimino, or 1-piperidinyl compounds include those compounds wherein R⁰, R¹, R², and R³ are each independently -H, -OH or -OCH₃.

Although the free-base or acid forms of formula I compounds can be used in the methods of the present invention, it is preferred to prepare and use a pharmaceutically acceptable salt form. Thus, the compounds used in the methods of this invention form pharmaceutically acceptable acid or base addition salts with a wide variety of organic and

inorganic acids and bases, and include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Such salts are also part of this invention. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric, and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanolic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, b-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzenesulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like. Preferred salts are the hydrochloride and oxalate salts.

Typical bases used to form pharmaceutically acceptable addition salts would be inorganic bases, such as, sodium hydroxide, potassium hydroxide, alkali carbonates or bicarbonates, calcium carbonate, magnesium carbonate, and the like. Additionally, organic bases may be utilized to form addition salts, e.g., alkyl amines, such as, triethylamine, dimethylamine, i-propylamine, and the like.

The pharmaceutically acceptable acid or base addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid or base. The reactants are generally combined in a mutual solvent such as diethyl ether or ethyl acetate. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.

Specific examples of compounds contemplated as falling within the scope of the present invention include, but are not limited to the following compounds and their

pharmaceutically acceptable salts:

11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-d]thiophen-3-ol;

5 11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-d]thiophene-3,8-diol;

11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-d]thiophene-3,10-diol;

11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-d]thiophene-3,9-diol;

10 10-Fluoro-12-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracen-3-ol;

12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,10-diol;

15 12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,9-diol;

12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,11-diol;


12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,8-diol.

20

The compounds of formula (I) can be prepared by utilizing procedures and techniques well known and appreciated by one of ordinary skill in the art. A general synthetic scheme for preparing compounds of formula (I) wherein X is -S- is set forth in Scheme A, wherein all substituents, unless otherwise indicated, are previously defined.

25

SCHEME A



- 5 In Scheme A, R^{0a}, R^{1a}, R^{2a}, and R^{3a} are each independently -H or -OPg, where Pg is a hydroxy protecting group and R^{2a} and R^{3a} can further be halo. In compounds of formula (2), (3), et seq., the Pg protecting groups R^{1a}, R^{2a}, and R^{3a} are phenolic protecting groups of the type taught by T. Greene, *et al.* in Chapter 3 of "Protective Groups in Organic Synthesis," Second Edition, John Wiley & Sons, Inc., New York, 1991, pp.143-
 10 170. The preferred protecting groups are alkyl ether groups, with methyl being particularly preferred.

In Scheme A, step 1, the (2-benzyl-benzo[b]thiophen-3-yl)-(4-substituted-phenyl)-methanone of formula (3) is prepared by reacting a dimethylaminobenzothiophene of formula (2) with a suitably protected benzylmagnesium halide under Grignard conditions,
 15 where Pg is a phenol protecting group such as a methyl or benzyl ether. The Grignard reactions are of the type taught by Godfrey (US Pat. No. 5,420,349).

For example, the dimethylaminobenzothiophene (2) is reacted with a suitable benzylmagnesium chloride under anhydrous conditions in a suitable aprotic organic

solvent such as anhydrous tetrahydrofuran. The benzylmagnesium chloride is preferably present in the reaction zone in a molar excess to dimethylaminobenzothiophene (2) of about 1.1 to about 3 equivalents. The reaction is carried out at a suitable temperature, preferably at room temperature, for a period of time ranging from about 1 to about 12
5 hours. The reaction is then quenched with a proton source such as, for example, sodium bicarbonate or methanol. The solvent is removed and the resulting mixture may be extracted, concentrated and purified according to techniques well known in the art, and the crude (2-benzyl-benzo[b]thiophen-3-yl)-(4-substituted-phenyl)-methanone (3) product may be used without further purification.

10 Appropriate dimethylaminobenzothiophenes (2) are known in the art, Grese et al., *J. Med. Chem.* 40(2), 146-147 (1997), U.S. Pat No. 5466810 issued Nov. 14, 1995, U.S. Pat. No 5,420,349 issued May 30 1995, U.S. Pat. No. 5,792,870, issued Aug. 11, 1998, and U.S. Pat. No. 5,554,755, issued Sept. 10, 1996, or are prepared by techniques and procedures well known in the art.

15 In Scheme A, step 2, (2-benzyl-benzo[b]thiophen-3-yl)-(4-substituted-phenyl)-methanol (4) is prepared by reducing (2-benzyl-benzo[b]thiophen-3-yl)-(4-substituted-phenyl)-methanone (3) with a suitable reducing agent.

For example, (2-benzyl-benzo[b]thiophen-3-yl)-(4-substituted-phenyl)-methanone (3) is contacted with an excess of a suitable reducing agent, such as diisobutylaluminum
20 hydride (DIBAL), lithium aluminum hydride (LAH), aluminum hydride or borane dimethyl sulfide complex. The reaction is carried out in a suitable solvent, such as tetrahydrofuran or diethyl ether. The reaction is typically carried out at temperatures of from 0°C to the refluxing temperature of the solvent. Typically, the reaction requires from about 15 minutes to about 36 hours. The (2-benzyl-benzo[b]thiophen-3-yl)-(4-
25 substituted-phenyl)-methanol (4) can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

In Scheme A, step 3, the cyclized product of formula (IA) is prepared by subjecting (2-benzyl-benzo[b]thiophen-3-yl)-(4-substituted-phenyl)-methanol (4) to an acid-catalyzed cyclization.


For example, (2-benzyl-benzo[b]thiophen-3-yl)-(4-substituted-phenyl)-methanol (4) is diluted with a suitable solvent or solvent mixture, such as tetrahydrofuran and water followed by the addition of a suitable acid, such as hydrochloric acid. The reaction mixture is then heated gently for a period of time ranging from about 5 to 30 minutes, diluted with a suitable organic solvent, such as methylene chloride, and quenched with a suitable base, such as sodium carbonate, sodium bicarbonate, potassium carbonate, or potassium dicarbonate. The cyclized product of formula (IA) can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

For compounds of formula (IA) when a hydroxy group is desired at R^0 , R^1 , R^2 , and/or R^3 , a compound of formula (IA) is deprotected with a suitable deprotecting agent such as BBr_3 , or sodium ethanethiolate (NaSEt). The BBr_3 reaction is conveniently carried out in a suitable organic solvent such as dichloromethane or dichloroethane while the NaSEt reaction can be conveniently carried out in DMF, THF, or N-methylpyrrolidinone (NMP). The reaction is quenched with water and diluted with a suitable organic solvent such as methylene chloride. The deprotected product where R^0 , R^1 , R^2 , and/or R^3 are hydroxy can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

Alternatively, a one-pot cyclization/deprotection transformation can be achieved by subjecting compounds of formula (4) to BBr_3 . The reaction is conveniently carried out in a suitable organic solvent such as dichloromethane or dichloroethane. The deprotected product of formula (IA) where R^0 , R^1 , R^2 , and/or R^3 are hydroxy can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

A general synthetic scheme for preparing compounds of formula (I) wherein X is $-CH=CH-$ is set forth in Scheme B, wherein all substituents, unless otherwise indicated, are previously defined.

SCHEME B



In Scheme B, R^{0a} , R^{1a} , R^{2a} , and R^{3a} are each independently $-H$ or $-OPg$, where Pg is a hydroxy protecting group and R^{2a} and R^{3a} can further be halo. In compounds of formula (5), (6), et seq., the Pg protecting groups R^{0a} , R^{1a} , R^{2a} , and R^{3a} are phenolic protecting groups capable of withstanding the conditions of the Friedel-Crafts acylation reaction and are of the type taught by T. Greene, *et al.* in Chapter 3 of "Protective Groups in Organic Synthesis," Second Edition, John Wiley & Sons, Inc., New York, 1991, pp.143-170. The preferred protecting groups are alkyl ether groups, with methyl being particularly preferred.

The activating group, A, is selected from groups well known in the art to activate acids for the purposes of carrying out Friedel-Crafts acylation reactions and include the acid halides, such as fluoride, chloride and bromide; mixed acid anhydrides with C_1-C_6 alkanolic acids; C_1-C_6 alkylsulfonic acids, arylsulfonic acids, perfluorinated C_1-C_6 alkanolic acids, C_1-C_6 alkylcarbonates, arylcarbonates, and the like. The preferred compounds of formula (8a) are those in which A is halogen, most preferably chlorine.

In Scheme B, step 1, a substituted naphthyl methanone of formula (6) is prepared by conducting a Friedel-Crafts acylation of a substituted naphthyl of formula (5) with a substituted benzoyl derivative of formula (5a).

For example, the acylation reaction between (5) and (5a) is carried out in an inert organic solvent in the presence of a Lewis acid catalyst. Suitable solvents include halogenated hydrocarbons such as dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride, chlorobenzene, dichlorobenzene and the like. The amount of solvent is not critical, but is generally sufficient to enable efficient mixing of the reaction components. Suitable Lewis acid catalysts for the Friedel-Crafts acylation reaction between (5) and (5a) include anhydrous aluminum, boron, or zinc halides with aluminum chloride being preferred. Temperature and time of reaction will vary, depending upon the choice of reaction solvent, Lewis acid catalyst, and activating group, A. Generally, reactions are carried out at temperatures below or at ambient to below or at the reflux temperature of the solvent. Reaction times vary from several minutes to about forty-eight hours. The progress of the reaction toward completion can be followed by well-known techniques such as thin-layer chromatographic analysis of aliquots of the reaction mixture during the course of the reaction.

Typically, the reaction is conducted using 1.0 to 1.5 equivalents of compound (5a) for each equivalent of compound (5), with more of the activated benzoyl compound added during the course of the reaction as needed to drive the reaction to completion. The amount of Lewis acid catalyst employed ranges from between about 0.1 to about 5
5 equivalents. The substituted naphthyl methanone of formula (6) can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

Appropriate substituted benzoyl derivatives of formula (5a) can be prepared as described herein from its appropriate benzoic acid derivative as set forth analogously in
10 U.S. Pat. No. 5,962,475, the disclosure of which is hereby incorporated by reference. Appropriate benzoic acid derivatives of compounds of formula (5a) are set forth in U.S. Pat. No. 4,418,068, U.S. Pat. No. 5,631,369, and U.S. Pat. No. 5,852,193, the disclosures of which are hereby incorporated by reference.


In Scheme B, step 2, the 2-hydroxy-6-substituted-naphthalen-1-yl-methanone of
15 formula (7) is prepared by selectively deprotecting the substituted naphthyl methanone of formula (6).

For example, the naphthyl methanone of formula (6) is reacted with a demethylation reagent such as boron tribromide, boron trichloride, or boron triiodide, or with $AlCl_3$. The reaction is conducted under an inert atmosphere such as nitrogen, with
20 one or more moles of the reagent per mole of methoxy group to be demethylated. Appropriate solvents for this reaction are those solvents or mixture of solvents which remain inert throughout the demethylation reaction. Halogenated solvents such as dichloromethane, 1,2-dichloroethane, chloroform, methylene chloride, or aromatic solvents such as benzene or toluene are preferred. The temperature employed in this
25 reaction of the present process should be sufficient to effect completion of the demethylation reaction. However, it is advantageous to keep the temperature below $0^\circ C$ in order to maximize selectivity for demethylation of the desired methoxy group and avoid the formation of undesirable by products, especially the dihydroxy analog arising from excessive demethylation. Under the preferred reaction conditions, a selectively
30 dealkylated product will be formed after stirring the reaction for about 1 to 24 hours. After quenching the reaction, the 2-hydroxy-6-substituted-naphthalen-1-yl-methanone of formula (7) can be isolated and purified by techniques well known in the art, such as

extraction, evaporation, trituration, chromatography, and recrystallization.

In Scheme B, step 3, a 2-L-substituted-6-substituted-naphthalen-1-yl-methanone of formula (8) is prepared by converting the hydroxy group of the 2-hydroxy-6-substituted-naphthalen-1-yl-methanone of formula (7) to an appropriate activating group.

5 An appropriate activating group, L_1 , is one which is compatible with palladium-mediated coupling conditions and can be displaced by a benzylzinc halide of the formula



where Hal is a halo group, preferably chloro. Appropriate activating groups, L_1 , include bromo, iodo, and most preferably trifluoromethanesulfonate.

10 For example, compounds in which L_1 is trifluoromethanesulfonate are formed by contacting an appropriate 2-hydroxy-6-substituted-naphthalen-1-yl-methanone of formula (7) with a molar excess of trifluoromethanesulfonyl chloride. The reaction is carried out in a suitable solvent, such as dichloromethane, chloroform, toluene, benzene, or pyridine. The reaction is carried out in the presence of a suitable base, such as triethylamine,
15 diisopropylethyl amine, or pyridine. Generally the reaction is carried out at temperatures of from -20°C to 50°C . Generally, the reactions require from 30 minutes to 24 hours. The product can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

In Scheme B, step 4, a [6-substituted-2-(substituted-benzyl)-naphthalen-1-yl]-[4-substituted-phenyl]-methanone of formula (9) may be prepared by coupling 2-L-substituted-6-substituted-naphthalen-1-yl-methanone of formula (8) to a benzylzinc halide
20 of formula (8a) using standard palladium-mediated coupling procedures [see, e.g., Knochel et al. *Org. Lett.* 1999, 1, 1323].

For example, a slight excess of 2-alkoxybenzylzinc halide (8a) is added with each
25 equivalent of 2-L-substituted-6-substituted-naphthalen-1-yl-methanone of formula (8) in the presence of a palladium catalyst and an appropriate base in an inert solvent, such as toluene, N-methylpyrrolidinone/toluene, or 1,2-dimethoxyethane. Although various palladium catalysts drive such coupling reactions, the catalyst selected is usually reaction-specific. The use of a bis(dibenzylideneacetone)palladium - $\text{Pd}(\text{dba})_2$ catalyst in the

present reaction is a preferred catalyst. Tetrabutylammonium iodide (Bu₄NI) as an additive has been shown to improve yields and reaction times of similar couplings (Knochel et al. *Org. Lett.* 1999, 1, 1323). The temperature employed in this step should be sufficient to effect completion of the coupling reaction. Typically, gently heating the reaction mixture for a period from about 2 to about 8 hours is adequate. The product (9) can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

Compounds of formula (8a) are either commercially available or derived from commercially available compounds via procedures well known to one of ordinary skill in the art [see, e.g., *Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, Fourth Edition, 3-16, (J. March, ed., John Wiley & Sons, Inc. 1992)].

In Scheme B, step 5, [6-substituted-2-(substituted-benzyl)-naphthalen-1-yl]-[4-substituted-phenyl]-methanol (10) is prepared by reducing [6-substituted-2-(substituted-benzyl)-naphthalen-1-yl]-[4-substituted-phenyl]-methanone (9) with a suitable reducing agent according to procedures set forth in Scheme A, step 2.

In Scheme B, step 6, the cyclized product of formula (IB) is prepared by subjecting [6-substituted-2-(GH-benzyl)-naphthalen-1-yl]-[4-substituted-phenyl]-methanol (11) to an acid-catalyzed cyclization according to procedures set forth in Scheme A, step 3.

When a hydroxy group is desired at R⁰, R¹, R², and/or R³, a compound of formula (IB) can be deprotected, isolated and purified according to procedures set forth previously in Scheme A.

Alternatively a one-pot cyclization reaction can be effected using BBR₃, as set forth previously in Scheme A.

When a -OC(O)(C₁-C₆ alkyl) or -OC(O)C₆H₅ group is desired at R⁰, R¹, R², and/or R³ a mono-, di-, tri-, or tetrahydroxy compound of formula I, is reacted with an agent such as acyl chloride, bromide, cyanide, or azide, or with an appropriate anhydride or mixed anhydride. The reactions are conveniently carried out in a basic solvent such as pyridine, lutidine, quinoline or isoquinoline, or in a tertiary amine solvent such as triethylamine, tributylamine, methylpiperidine, and the like. The reaction also may be carried out in an inert solvent such as ethyl acetate, dimethylformamide, dimethylsulfoxide, dioxane, dimethoxyethane, acetonitrile, acetone, methyl ethyl ketone,

and the like, to which at least one equivalent of an acid scavenger, such as a tertiary amine, has been added. If desired, acylation catalysts such as 4-dimethylaminopyridine or 4-pyrrolidinopyridine may be used. See, e.g., Haslam, *et al.*, Tetrahedron, 36:2409-2433 (1980).

5 The acylation reactions which provide the aforementioned R⁰, R¹, R², and/or R³ groups are carried out at moderate temperatures in the range from about -25°C to about 100°C, frequently under an inert atmosphere such as nitrogen gas. However, ambient temperature is usually adequate for the reaction.

Such acylations of the hydroxy group also may be performed by acid-catalyzed
10 reactions of the appropriate carboxylic acids in inert organic solvents or neat. Acid catalysts such as sulfuric acid, polyphosphoric acid, methanesulfonic acid, and the like are used.

The aforementioned R⁰, R¹, R², and/or R³ groups also may be provided by forming an active ester of the appropriate acid, such as the esters formed by such known
15 reagents as dicyclohexylcarbodiimide, acylimidazoles, nitrophenols, pentachlorophenol, N-hydroxysuccinimide, and 1-hydroxy-benzotriazole. See, e.g., Bull. Chem. Soc. Japan, 38:1979 (1965), and Chem. Ber., 788 and 2024 (1970).

When a compound is desired in which R⁰, R¹, R², and/or R³ are -OSO₂(C₄-C₆ alkyl), the suitable starting mono-, di- or trihydroxy compound is reacted with, for
20 example, a derivative of the appropriate sulfonic acid such as a sulfonyl chloride, bromide, or sulfonyl ammonium salt, as taught by King and Monoir, J. Am. Chem. Soc., 97:2566-2567 (1975). The mono-, di-, tri-, or tetrahydroxy compound also can be reacted with the appropriate sulfonic anhydride. Such reactions are carried out under conditions such as were explained above in the discussion of reaction with acid halides and the like.

25 Compounds of formula (I) can be prepared so that R⁰, R¹, R², and/or R³ are different biological protecting groups or, preferably, the same biological protecting group. Preferred protecting groups include -CH₃, -C(O)C(CH₃)₃, -C(O)C₆H₅, and -SO₂(CH₂)₃CH₃.


Compounds of formula (5a) wherein Y is -S-, -NH-, -NMe-, or -CH₂- may be
30 prepared analogously according to procedures well known in the art. For example, preparative syntheses of compounds of formula (5a) are taught by C.R. Schmidt *et al.*, Bioorg. Med. Chem. Lett. 9 (1999) 523-528.

-19-

All solvents were ACS grade and were used as supplied. All reagents were commercially available and used without further purification unless otherwise noted. LCMS data was recorded on a Hewlett Packard 1100 series instrument. The method used was 5% acetonitrile - 95% water (0.05% TFA) to 95% acetonitrile - 5% water (0.05% TFA) over two minutes and hold for three minutes on a Waters Symmetry C18 2.1x50mm
5 column at 35°C. ¹H NMR spectra were recorded at 300 MHz on a Varian 300 spectrometer unless otherwise noted.

PREPARATION 1

10 (2-Benzyl-6-methoxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-
methanone




Add benzylmagnesium bromide (1.5 mL, 3M) to a stirred solution of (2-
dimethylamino-6-methoxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-
15 methanone (1.0 g, 2.28 mmol) in THF (10 mL) at room temperature (r.t.). Stir the mixture
for 30 min. and quench with sat. NaHCO₃. Dilute the reaction mixture with CH₂Cl₂ and
wash with water and brine, dry over MgSO₄, filter and concentrate. Use the crude product
without further purification.

20

-20-

PREPARATION 2

(2-Benzyl-6-methoxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-
methanol




5 Dissolve crude (2-benzyl-6-methoxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone in THF (10 mL) at r.t. Add LAH solution (3 mL of 1 M/THF) dropwise while stirring. Continue stirring for 20 min. and quench with aq. NaHCO₃. Dilute the reaction mixture with CH₂Cl₂ and wash with water and brine, dry over MgSO₄, filter and concentrate. Purify the crude product by flash chromatography (0
10 – 5% (2M NH₃ in MeOH)/CH₂Cl₂) to yield (2-benzyl-6-methoxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanol (755 mg, 84%, 2 steps).

¹H NMR: (CDCl₃, 300 MHz) δ 7.58 (d, J = 8.5 Hz, 1H), 7.17 – 7.30 (m, 7H), 6.77 – 6.83 (m, 3H), 6.25 (s, 1H), 4.25 (s, 2H), 4.02 (t, J = 6.2 Hz, 2H), 3.78 (s, 3H), 3.20 (br. s, 1H), 2.70 (t, J = 6.2 Hz, 2H), 2.47 (br. s, 4H), 1.56 – 1.63 (m, 4H), 1.40 – 1.47 (m, 2H)

15

EXAMPLE 1

11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-d]thiophen-3-
ol trifluoroacetate



20 Add BBr₃ (15 uL) to a stirred solution of (2-benzyl-6-methoxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanol (100 mg, 0.21 mmol) in CH₂Cl₂ (2.5 mL). Stir at r.t. for 30 min. and quench with MeOH and 2-methyl-1-butene which acts as a bromine scavenger. Load the crude product on an SCX column, wash with MeOH and elute with 1M NH₃/MeOH. Purify the product by preparative HPLC to afford the

-21-


trifluoroacetate salt of 11-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-d]thiophen-3-ol (73 mg, 65%).

^1H NMR: (CD_3OD , 300 MHz) δ 7.25 - 7.34 (m, 3H), 7.13 - 7.20 (m, 4H), 6.82 (d, $J = 8.8$ Hz, 2H), 6.70 (dd, $J = 8.8, 2.2$ Hz, 2H), 5.38 (t, $J = 6.2$ Hz, 1H), 4.38 (dd, $J = 20.9$ Hz, 3.7 Hz, 1H), 4.12 - 4.23 (m, 3H), 3.53 (br. d, $J = 11.7$ Hz, 2H), 3.44 (t, $J = 4.8$ Hz, 2H), 2.97 (br. t, $J = 12.1$ Hz, 2H), 1.66 - 1.92 (m, 5H), 1.45 - 1.55 (m, 1H).

LCMS: 3.016 min; $m/z = 456$ ($\text{M}+\text{H}$) $^+$ -TFA

EXAMPLE 2

10 11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-d]thiophene-3,8-diol trifluoroacetate



The title compound is prepared using the same procedure as outlined for Example 1 above, using commercially available 3-methoxybenzylmagnesium chloride instead of benzylmagnesium bromide.


^1H NMR: (CD_3OD , 300 MHz) δ 7.29 (d, $J = 8.8$ Hz, 1H), 7.12 - 7.16 (m, 3H), 7.07 (d, $J = 8.4$ Hz, 1H), 6.80 (d, $J = 8.8$ Hz, 2H), 6.67 - 6.72 (m, 2H), 6.61 (dd, $J = 8.4, 2.6$ Hz, 1H), 5.24 (t, $J = 3.0$ Hz, 1H), 4.30 (dd, $J = 20.9, 3.3$ Hz, 1H), 4.19 (t, $J = 5.1$ Hz, 2H), 4.06 (dd, $J = 20.9, 2.9$ Hz, 1H), 3.51 (br. d, $J = 11.7$ Hz, 2H), 3.41 (t, $J = 4.8$ Hz, 2H), 2.94 (br. t, $J = 12.5$ Hz, 2H), 1.67 - 1.90 (m, 5H), 1.44 - 1.53 (m, 1H).

LCMS: 2.70 min; $m/z = 472$ ($\text{M}+\text{H}$) $^+$ -TFA

-22-

EXAMPLE 3

11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-d]thiophene-3,10-diol trifluoroacetate



5 The title compound is prepared using the same procedure as outlined for Example 1 above, using commercially available 3-methoxybenzylmagnesium chloride instead of benzylmagnesium bromide.


¹H NMR: (CD₃OD, 300 MHz) δ 7.49 (d, J = 8.8 Hz, 1H), 7.26 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 2.2 Hz, 1H), 7.03 (t, J = 7.7 Hz, 1H), 6.74 – 6.84 (m, 4H), 6.63 (d, J = 7.7 Hz, 1H),
 10 5.62 (br. s, 1H), 4.37 (dd, J = 20.5, 2.6 Hz, 1H), 4.09 – 4.21 (m, 3H), 3.51 (br. d, J = 12.1 Hz, 2H), 3.41 (t, J = 4.8 Hz, 2H), 2.94 (br. t, J = 12.1 Hz, 2H), 1.66 – 1.93 (m, 5H), 1.44 – 1.53 (m, 1H).

LCMS: 2.87 min; m/z = 472 (M+H)⁺-TFA

15

EXAMPLE 4

11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-d]thiophene-3,9-diol



The title compound is prepared using the same procedure as outlined for Scheme 1
 20 above, using commercially available 4-methoxybenzylmagnesium chloride instead of benzylmagnesium bromide.


-23-

^1H NMR: (CD_3OD , 300 MHz) δ 7.31 (d, $J = 8.8$ Hz, 1H), 6.98 – 7.20 (m, 4H), 6.84 (d, $J = 8.8$ Hz, 2H), 6.63 – 6.74 (m, 3H), 5.29 (br. s, 1H), 4.23 – 4.30 (m, 2H), 4.08 (d, $J = 20.5$ Hz, 2H), 3.45 – 3.60 (m, 4H), 2.95 – 3.06 (m, 2H), 1.71 – 1.92 (m, 5H), 1.48 – 1.5 (m, 1H).

5

PREPARATION 3

(2,6-Dimethoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone




- In a dry round bottom flask equipped with stir bar, temperature probe and N_2 line,
10 dissolve 2,6-dimethoxynaphthalene (1.0 eq) in CH_2Cl_2 (5 volume equivalents) at ambient
temperature. Cool the solution to 0°C in with an ice bath, and add 4-(2-piperidin-1-yl-
ethoxy)-benzoyl chloride (1.1 eq). Add aluminum chloride (2.0 eq). Once the reaction is
determined to be complete, quench the reaction slowly with 1 N NaOH and dilute with
additional water and CH_2Cl_2 . Wash the aqueous layer with (1 x 20 mL) of CH_2Cl_2 .
15 Combine the organic extracts and wash with brine and dry (Na_2SO_4). Recrystallize the
crude product from methanol to give (2,6-dimethoxy-naphthalen-1-yl)-[4-(2-piperidin-1-
yl-ethoxy)-phenyl]-methanone (average yield 68%).

-24-

PREPARATION 4

(2-Hydroxy-6-methoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone




Dissolve (2,6-Dimethoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone in CH_2Cl_2 (10 volume equivalents) in a 3-neck round bottom flask equipped with a pressure equalizing addition funnel, stirbar, and N_2 source. Cool the flask in an ice/brine bath and add 1.0 M BCl_3 solution in CH_2Cl_2 (1.2 equivalents) dropwise. The reaction solution turns dark red and the temperature initially increases to 5 °C. Within one hour, all starting material is consumed, as determined by TLC (1:1, Ether:Petroleum Ether). Quench the reaction with methanol (5 equivalents) and allow to warm to room temperature. Dilute the organic solution with CH_2Cl_2 (one volume equivalent) and add to a 1.0 M NaHCO_3 solution (5 volume equivalents) and stir for one hour. Separate the aqueous and organic layers. Wash the aqueous layer with CH_2Cl_2 (one volume) and the combine organic layers, wash with saturated NH_4Cl and dry over Na_2SO_4 . Purify the product via column chromatography (50/1 silica gel) eluting with CH_2Cl_2 /Hexanes (3/1) to yield (2-hydroxy-6-methoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (typical yield 87 %).

-25-

PREPARATION 5

Trifluoro-methanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester




5 Dissolve (2-hydroxy-6-methoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone in CH_2Cl_2 (10 volumes) in a three neck round bottom flask equipped with a stir bar and N_2 source and chill to 0°C in an ice/brine bath. Add pyridine (1.3 equivalents). Add trifluoromethane sulfonyl chloride (1.2 equivalents) via syringe over 15 minutes. The yellow slurry turns clear orange with this addition. The reaction is

10 determined to be complete by HPLC analysis after 15 minutes. Quench the reaction with H_2O (10 volumes), wash with 1 N HCl (5 volumes), wash with 1.0 N NaHCO_3 , and dry over Na_2SO_4 . After concentration, trifluoro-methanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester as a clean yellow foam is obtained in quantitative yield. Use the product without further purification.

15

PREPARATION 6

[2-(4-Fluoro-benzyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone




20 Add 4-fluorobenzylzinc chloride (4 mL of 0.5 M/THF) to a stirred solution of trifluoro-methanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester (525 mg), $\text{Pd}(\text{dba})_2$ (68 mg), dppf (66 mg) and Bu_4NI (1.1g) in THF/NMP (2 mL/1.5 mL) at room temperature. Heat the mixture to reflux for 2 h and quench with water. Dilute the mixture with CH_2Cl_2 and wash with water and brine, dry

-26-

over MgSO_4 , filter and concentrate. Load the crude product on an SCX cartridge, wash with MeOH and elute the product with 2M NH_3/MeOH . Purify the product by flash chromatography (0-5 % (2M NH_3 in $\text{MeOH}/\text{CH}_2\text{Cl}_2$) to afford [2-(4-fluoro-benzyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (380 mg, 78%)

PREPARATION 7

[2-(4-Fluoro-benzyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanol




10

Add LAH solution (2 mL, 1M/THF) to a stirred solution of [2-(4-fluoro-benzyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone (380 mg) in THF (5 mL) at room temperature. Heat the mixture to reflux for 1 h, cool to r.t. and quench with aq. NaHCO_3 . Dilute the mixture with CH_2Cl_2 and wash with water and brine, dry over MgSO_4 , filter and concentrate to afford [2-(4-fluoro-benzyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanol. Use the product without further purification.

15

EXAMPLE 5

20 10-Fluoro-12-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracen-3-ol



Add BBR_3 (0.3 mL) to crude [2-(4-fluoro-benzyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanol in CH_2Cl_2 (10 mL). Stir at r.t for 1 h and quench with MeOH and 2-methyl-2-butene. Load the crude product on an SCX cartridge,

-27-

wash with MeOH and elute with 2M NH₃/MeOH. Purify the product by flash chromatography (0-5 % (2M NH₃ in MeOH/CH₂Cl₂) to afford 10-fluoro-12-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracen-3-ol (258 mg, 72 %, 2 steps).


- 5 ¹H NMR: (CD₃OD, 300 MHz) δ 7.97 (d, J = 9.2 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.21 – 7.30 (m, 2H), 7.11 (d, J = 2.6 Hz, 1H), 7.04 (dd, J = 8.8, 2.6 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 6.97 (dt, J = 8.8, 2.6 Hz, 1H), 6.63 (d, J = 8.8 Hz, 2H), 5.89 (s, 1H), 3.86 – 4.09 (m, 2H), 3.88 (t, J = 5.5 Hz, 2H), 2.60 (t, J = 5.5 Hz, 2H), 2.42 (br. s, 4H), 1.50 – 1.60 (m, 4H), 1.35 – 1.42 (m, 2H)
- 10 LCMS: 3.24 min; m/z = 468 (M+H)⁺

Separate racemic 10-fluoro-12-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracen-3-ol into its enantiomers by chiral HPLC to afford EXAMPLE 6 and EXAMPLE 7.

15

EXAMPLE 8

12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,10-diol



- The title compound is prepared using the same procedure as outlined for Example 5 above, using commercially available 4-methoxybenzylzinc chloride instead of 4-fluorobenzylzinc chloride.
- 20

Purify the crude product by preparative HPLC to afford the trifluoroacetate salt of 12-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,10-diol.


- ¹H NMR: (CD₃OD, 300 MHz) δ 7.97 (d, J = 9.2 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 6.96 – 7.12 (m, 6H), 6.61 – 6.67 (m, 3H), 5.82 (s, 1H), 3.85 – 4.06 (m, 4H), 3.39 (br. d, J = 12.1 Hz, 2H), 3.25 (t, J = 5.1 Hz, 2H), 2.74 – 2.83 (m, 2H), 1.61 – 1.81 (m, 5H), 1.35 – 1.43 (m, 1H).
- 25

LCMS: 2.80 min; m/z = 466 (M+H)⁺ - TFA

-28-

EXAMPLE 9

12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,9-diol



- 5 The title compound is prepared using the same procedure as outlined above for Example 5 using commercially available 3-methoxybenzylzinc chloride instead of 4-fluorobenzylzinc chloride. Purify the crude product by preparative HPLC to afford the trifluoroacetate salt of 12-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,9-diol.
- 10 ^1H NMR: (CD_3OD , 300 MHz) δ 7.98 (d, $J = 9.2$ Hz, 1H), 7.55 (d, $J = 8.4$ Hz, 1H), 7.34 (dd, $J = 8.4, 2.9$ Hz, 2H), 7.12 (d, $J = 2.6$ Hz, 1H), 6.99 – 7.05 (m, 3H), 6.74 (d, $J = 2.2$ Hz, 1H), 6.67 (app. d, $J = 8.8$ Hz, 3H), 5.84 (s, 1H), 3.85 – 4.10 (m, 4H), 3.41 (br. d, $J = 11.7$ Hz, 2H), 3.26 – 3.32 (m, 2H), 2.81 (br. t, $J = 12.1$ Hz, 2H), 1.61 – 1.83 (m, 5H), 1.26 – 1.45 (1H).
- 15 LCMS: 2.77 min; $m/z = 466$ ($\text{M}+\text{H}$) $^+$ - TFA


Separate racemic 12-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,9-diol into its enantiomers using chiral HPLC to afford EXAMPLE 10 and EXAMPLE 11.

20

-29-

EXAMPLE 12

12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,11-diol



The title compound is prepared using the same procedure as outlined for Example 5 above using commercially available 3-methoxybenzylzinc chloride instead of 4-fluorobenzylzinc chloride. Purify the crude product by preparative HPLC to afford the trifluoroacetate salt of 12-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,11-diol.


¹H NMR: (CD₃OD, 300 MHz) δ 8.05 (d, J = 9.2 Hz, 1H), 7.6 (d, J = 8.4 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.11 – 7.18 (m, 3H), 6.97 – 7.08 (m, 3H), 6.81 (d, J = 7.3 Hz, 1H), 6.72 (d, J = 8.8 Hz, 2H), 6.40 (s, 1H), 4.17 (t, J = 5.1 Hz, 2H), 3.98 (ABq, J = 18.7 Hz, 2H), 3.49 (br. d, J = 7.0 Hz, 2H), 3.39 (t, J = 4.8 Hz, 2H), 2.92 (br. t, J = 12.5 Hz, 2H), 1.64 – 1.89 (m, 5H), 1.43 – 1.50 (m, 1H).

LCMS: 2.88 min; m/z = 466 (M+H)⁺ - TFA

15

EXAMPLE 13

12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,8-diol



The title compound is prepared using the same procedure as outlined for Example 5 above using commercially available 2-methoxybenzylzinc chloride instead of 4-fluorobenzylzinc chloride.

¹H NMR: (CD₃OD, 300 MHz) δ 7.95 (d, J = 9.2 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 2.6 Hz, 1H), 6.93 – 7.03 (m, 5H), 6.64 (t, J = 4.4 Hz, 1H), 6.48 (d, J = 8.4 Hz, 2H), 5.80 (s, 1H), 4.28 (d, J = 20.2 Hz, 1H), 3.82 (d, J = 19.8 Hz, 1H),

20

-30-

3.70 (t, J = 5.5 Hz, 2H), 2.55 (t, J = 5.5 Hz, 2H), 2.39 (br. s. 4H), 1.47 (m, 4H), 1.34 (br. s, 2H).

LCMS: 2.83 min; m/z = 466 (M+H)⁺

5

Biological Test Procedure

General Preparation Procedure

Competition binding assay is run in a buffer containing 50mM Hepes, pH 7.5,
10 1.5mM EDTA, 150mM NaCl, 10% glycerol, 1mg/ml ovalbumin and 5mM DTT, using
0.025 μ Ci per well ³H-Estradiol(NEN #NET517 at 118 Ci/mmol, 1 mCi/ml), 10 ng/well
ERAlpha or ERbeta receptor (PanVera). Competing compounds are added at 10 different
concentrations. Non-specific binding is determined in the presence of 1 μ M of 17-B
Estradiol. The binding reaction (140 μ l) is incubated for 4 hours at room temperature,
15 then 70 μ l of cold DCC buffer is added to each reaction (DCC buffer contains per 50 ml
of assay buffer, 0.75g of charcoal (Sigma) and 0.25g of dextran (Pharmacia)). Plates are
mixed 8 minutes on an orbital shaker at 4°C. Plates are then centrifuged at 3,000 rpm at
4°C for 10 minutes. An aliquot of 120 μ l of the mix is transferred to another 96-well,
white flat bottom plate (Costar) and 175 μ l of Wallac Optiphase "Hisafe 3" scintillation
20 fluid is added to each well. Plates are sealed and shaken vigorously on an orbital shaker.
After an incubation of 2.5hrs, read plates in a Wallac Microbeta counter. The data is used
to calculate an IC₅₀ and % Inhibition at 10 μ M. The K_d for ³H-Estradiol is determined by
saturation binding to ER alpha and ER beta receptors. The IC₅₀ values for compounds are
converted to K_i using Cheng-Prusoff equation and the K_d determined by saturation
25 binding assay.

Ishikawa human endometrial tumor cells are maintained in MEM (minimum
essential medium, with Earle's salts and L-Glutamine, Gibco BRL, Gaithersburg, MD),
supplemented with 10% fetal bovine serum (FBS) (V/V), (Gibco BRL). One day prior to
assay, growth media is changed to assay medium, DMEM/F-12 (3:1) (Dulbecco's
30 Modified Eagle Medium: Nutrient Mixture F-12, 3:1 Mixture, phenol red-free, Gibco
BRL) supplemented with 5% dextran coated charcoal stripped fetal bovine serum (DCC-
FBS) (Hyclone, Logen, UT), L-Glutamine (2mM), MEM sodium pyruvate (1 mM),
HEPES (N-[2-hydroxyethyl]piperazine-N' - [2-ethanesulfonic acid] 2 mM) all from

-31-

Gibco BRL). After an overnight incubation, ishikawa cells are rinsed with Dulbecco's Phosphate Buffered Saline (1X) (D-PBS) without Ca^{+2} and Mg^{+2} (Gibco BRL), and trypsinized by a 3 minute incubation with 0.25% Trypsin/EDTA, phenol red-free (Gibco BRL). Cells are resuspended in assay medium and adjusted to 250,000 cells/ml.

5 Approximately 25,000 cells in a 100ul media are added to flat-bottom 96 wells microculture plates (Costar 3596) and incubated at 37°C in a 5% CO₂ humidified incubator for 24 hours. The next day, serial dilutions of compounds are prepared in assay medium (at 6 times the final concentration in the assay). The assay is run in dual mode, agonist and antagonist modes. For the agonist mode, plates receive 25 µl/well of assay

10 medium followed by 25 µl/well of diluted compounds (at 6x the final concentrations). For the antagonist mode, plates receive 25 µl/well of 6 nM E₂ (β-Estradiol, Sigma, St. Louis, MO) followed by 25 µl/well of diluted compounds (at 6x the final concentrations). After an additional 48-hour incubation at 37°C in a 5% CO₂ humidified incubator, media is aspirated from wells and 100 µl fresh assay medium is added to each microculture. Serial

15 dilutions of compounds are prepared and added to the cells as described above. After an additional 72 hour incubation at 37°C in a 5% CO₂ humidified incubator, the assay is quenched by removing media and rinsing plates twice in Dulbecco's Phosphate Buffered Saline (1X) (D-PBS) (Gibco BRL). The plates are dried for 5 min and frozen at -70°C for at least 1 hour. The plates are then removed from the freezer and allowed to thaw at room

20 temperature. To each well, 100 µl of 1-Step™ PNPP (Pierce Chemical Company, Rockford, IL) is added. After a 20-minute incubation, plates are read on a spectrophotometer at 405nm. The data is fitted to a linear interpolation to derive EC₅₀ (for agonist mode) or IC₅₀ (for antagonist mode) values. For the agonist mode, a % efficacy for each compound is calculated versus the response to Tamoxifen. For the antagonist

25 mode, a % efficacy for each compound is calculated versus E₂ (1nM) alone.

MCF-7 breast adenocarcinoma cells (ATCC HTB 22) are maintained in MEM (minimal essential medium, phenol red-free, Gibco BRL) supplemented with 10% fetal bovine serum (FBS) (V/V), L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES ((N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid])10 mM}, non-essential amino

30 acids(0.1mM)and Penicillin Streptomycin(1X). Seven days prior to assay, MCF-7 cells are switched to assay media which is the same as maintenance medium except supplemented with 10% dextran-coated charcoal-stripped fetal bovine serum (DCC-FBS)

-32-

assay medium in place of 10% FBS. MCF-7 cells are removed from flasks using 10X Trypsin EDTA (phenol red free, Gibco BRL) and diluted to 1X in (Ca⁺⁺/Mg⁺⁺ free HBSS (phenol red-free). Cells are adjusted to 80,000 cells/ml in assay medium. Approximately 8,000 cells (100 μ l) are added to each well in 96 well Cytostar T

5 scintillation plates (Amersham) and incubated at 37°C in a 5% CO₂ humidified incubator for 24 hours to allow cell adherence and equilibration after transfer. Serial dilutions of drugs are prepared in assay medium at 4x the final desired concentration). A 50 μ l aliquot of drug dilutions (at 4x the final assay concentration) is transferred to duplicate wells followed by 50 μ l assay medium for the agonist mode or 50 μ l of 40pM of E2 for the

10 antagonist mode to a final volume of 200 μ l. For each of the agonist plates, a basal level (media) and a maximum stimulated level (with 1 μ M E2) is determined. For each of the antagonist plates, a basal level (media) and a E2 (10pM) alone control is determined. After an additional 48 hours at 37°C in a 5% CO₂ humidified incubator, 20 μ l of assay medium containing 0.01 μ Ci of ¹⁴C-thymidine (52 mCi/mmol, 50 μ Ci/ μ l, Amersham) is

15 added to each well. The plates are incubated overnight in the same incubator and then counted on the Wallac Microbeta counter. The data is averaged to calculate an IC₅₀ and % inhibition @ 1 μ M for the antagonist mode. For the agonist mode, an EC₅₀ and percent of maximum E2 stimulation and concentration of maximum stimulation is calculated.

20

TABLE

Cmpnd (Ex. No.)	ER binding		MCF-7	Ishikawa		
	K _i (ER α) (nM)	K _i (ER β) (nM)	MCF-7 IC ₅₀ (nM)	Ishikawa EC ₅₀ (nM)	Agonist % Eff	IC ₅₀ (nM)
1	2	5	17	3	77	712
2	1	1	1	0.5	103	45
3	3	14	42	3	135	682
4	1	1	1	1	56	53
5	3	31	91	11	79	610
6	70	149	740	116	69	NC
7	1	9	9	3	72	440
8	1	3	7	3	75	130
9	1	4	2	1	27	31
10	1	5	23	3	56	156

	ER binding		MCF-7	Ishikawa		
11	1	4	2	1	19	28
12	8	40	68	28	77	582
13	1	5	3	1	121	50

NC = Not Calculated

General Rat Preparation Procedure

Seventy-five day old (unless otherwise indicated) female Sprague Dawley rats (weight range of 200 to 225g) are obtained from Charles River Laboratories (Portage, MI). The animals are either bilaterally ovariectomized (OVX) or exposed to a Sham surgical procedure at Charles River Laboratories, and then shipped after one week. Upon arrival, they are housed in metal hanging cages in groups of 3 or 4 per cage and have *ad libitum* access to food (calcium content approximately 0.5%) and water for one week. Room temperature is maintained at $22.2^{\circ} \pm 1.7^{\circ}\text{C}$ with a minimum relative humidity of 40%. The photoperiod in the room was 12 hours light and 12 hours dark.

Dosing Regimen Tissue Collection: After a one week acclimation period (therefore, two weeks post-OVX) daily dosing with a compound of formula (I) ("F-I") is initiated. 17α -ethynyl estradiol or F-I is given orally, unless otherwise stated, as a suspension in 1% carboxymethylcellulose or dissolved in 20% cyclodextrin. Animals are dosed daily for 4 days. Following the dosing regimen, animals are weighed and anesthetized with a ketamine: Xylazine (2:1, v:v) mixture and a blood sample is collected by cardiac puncture. The animals are then sacrificed by asphyxiation with CO_2 , the uterus is removed through a midline incision, and a wet uterine weight is determined. 17α -ethynyl estradiol is obtained from Sigma Chemical Co., St. Louis, MO.

Cardiovascular Disease/Hyperlipidemia

The blood samples from above are allowed to clot at room temperature for 2 hours, and serum is obtained following centrifugation for 10 minutes at 3000 rpm. Serum cholesterol is determined using a Boehringer Mannheim Diagnostics high performance cholesterol assay. Briefly the cholesterol is oxidized to cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide is then reacted with phenol and 4-aminophenazone in the presence of peroxidase to produce a p-quinone imine dye, which is read

spectrophotometrically at 500 nm. Cholesterol concentration is then calculated against a standard curve. The entire assay is automated using a Biomek Automated Workstation.

Uterine Eosinophil Peroxidase (EPO) Assay

5 The uteri from above are kept at 4°C until time of enzymatic analysis. The uteri are then homogenized in 50 volumes of 50 mM Tris buffer (pH - 8.0) containing 0.005% Triton X-100. Upon addition of 0.01% hydrogen peroxide and 10 mM O-phenylenediamine (final concentrations) in Tris buffer, increase in absorbance is monitored for one minute at 450 nm. The presence of eosonophils in the uterus is an
10 indication of estrogenic activity of a compound. The maximal velocity of a 15 second interval is determined over the initial, linear portion of the reaction curve.

Inhibition of Bone Loss (Osteoporosis) Test Procedure

 Following the general preparation procedure described above, the rats are treated
15 daily for thirty-five days (6 rats per treatment group) and sacrificed by carbon dioxide asphyxiation on the 36th day. The thirty-five day time period is sufficient to allow maximal reduction in bone density, measured as described herein. At the time of sacrifice, the uteri are removed, dissected free of extraneous tissue, and the fluid contents are expelled before determination of wet weight in order to confirm estrogen deficiency
20 associated with complete ovariectomy. Uterine weight is routinely reduced about 75% in response to ovariectomy. The uteri are then placed in 10% neutral buffered formalin to allow for subsequent histological analysis.

 The right femurs are excised and digitized X-rays generated and analyzed by an image analysis program (NIH image) at the distal metaphysis. The proximal aspect of the
25 tibiae from these animals are also scanned by quantitative computed tomography. In accordance with the above procedures, F-I or ethynyl estradiol (EE₂) in 20% hydroxypropyl β-cyclodextrin are orally administered to test animals. F-I is also useful in combination with estrogen or progestin.

30 Uterine Fibrosis Test Procedures

 Test 1: Between 3 and 20 women having uterine fibrosis are administered F-I. The amount of compound administered is from 0.1 to 1000 mg/day, and the period of

administration is 3 months. The women are observed during the period of administration, and up to 3 months after discontinuance of administration, for effects on uterine fibrosis.

Test 2: The same procedure is used as in Test 1, except the period of administration is 6 months.

5 Test 3: The same procedure is used as in Test 1, except the period of administration is 1 year.

Test 4: Prolonged estrogen stimulation is used to induce leiomyomata in sexually mature female guinea pigs. Animals are dosed with estradiol 3-5 times per week by injection for 2-4 months or until tumors arise. Treatment consisting of F-I or vehicle is administered daily for 3-16 weeks and then animals are sacrificed and the uteri harvested and analyzed for tumor regression.

10 Test 5: Tissue from human leiomyomas are implanted into the peritoneal cavity and/or uterine myometrium of sexually mature, castrated, female, nude mice. Exogenous estrogen is supplied to induce growth of the explanted tissue. In some cases, the harvested tumor cells are cultured *in vitro* prior to implantation. Treatment consisting of F-I or vehicle is supplied by gastric lavage on a daily basis for 3-16 weeks and implants are removed and measured for growth or regression. At the time of sacrifice, the uteri are harvested to assess the status of the organ.

15 Test 6: Tissue from human uterine fibroid tumors is harvested and maintained, *in vitro*, as primary non-transformed cultures. Surgical specimens are pushed through a sterile mesh or sieve, or alternately teased apart from surrounding tissue to produce a single cell suspension. Cells are maintained in media containing 10% serum and antibiotic. Rates of growth in the presence and absence of estrogen are determined. Cells are assayed for their ability to produce complement component C3 and their response to growth factors and growth hormone. *In vitro* cultures are assessed for their proliferative response following treatment with progestins, GnRH, F-I, and vehicle. Levels of steroid hormone receptors are assessed weekly to determine whether important cell characteristics are maintained *in vitro*. Tissue from 5-25 patients is utilized.

25 Test 7: F-I's ability to inhibit estrogen-stimulated proliferation of leiomyoma-derived ELT cell lines is measured substantially as described in Fuchs-Young, et al., "Inhibition of Estrogen-Stimulated Growth of Uterine Leiomyomas by Selective Estrogen

30

Receptor Modulators”, Mol. Car., 17(3):151-159 (1996), the teachings of which are herein incorporated by reference.

Endometriosis Test Procedures

5 Test 1: Twelve to thirty adult CD strain female rats are used as test animals. They are divided into three groups of equal numbers. The estrous cycle of all animals is monitored. On the day of proestrus, surgery is performed on each female. Females in each group have the left uterine horn removed, sectioned into small squares, and the squares are loosely sutured at various sites adjacent to the mesenteric blood flow. In
10 addition, females in Group 2 have the ovaries removed. On the day following surgery, animals in Groups 1 and 2 receive intraperitoneal injections of water for 14 days whereas animals in Group 3 receive intraperitoneal injections of 1.0 mg of F-I per kilogram of body weight for the same duration. Following 14 days of treatment, each female is sacrificed and the endometrial explants, adrenals, remaining uterus, and ovaries, where
15 applicable, are removed and prepared for histological examination. The ovaries and adrenals are weighed.

 Test 2: Twelve to thirty adult CD strain female rats are used as test animals. They are divided into two equal groups. The estrous cycle of all animals is monitored. On the day of proestrus, surgery is performed on each female. Females in each group have the
20 left uterine horn removed, sectioned into small squares, and the squares are loosely sutured at various sites adjacent to the mesenteric blood flow. Approximately 50 days following surgery, animals assigned to Group 1 receive intraperitoneal injections of water for 21 days whereas animals in Group 2 receive intraperitoneal injections of 1.0 mg of F-I per kilogram of body weight for the same duration. Following 21 days of treatment, each
25 female is sacrificed and the endometrial explants and adrenals are removed and weighed. The explants are measured as an indication of growth. Estrous cycles are monitored.

 Test 3: Autographs of endometrial tissue are used to induce endometriosis in rats and/or rabbits. Female animals at reproductive maturity undergo bilateral oophorectomy, and estrogen is supplied exogenously thus providing a specific and constant level of
30 hormone. Autologous endometrial tissue is implanted in the peritoneum of 5-150 animals and estrogen supplied to induce growth of the explanted tissue. Treatment consisting of a compound of the present invention is supplied by gastric lavage on a daily basis for 3-16

weeks, and implants are removed and measured for growth or regression. At the time of sacrifice, the intact horn of the uterus is harvested to assess status of endometrium.

5 Test 4: Tissue from human endometrial lesions is implanted into the peritoneum of sexually mature, castrated, female, nude mice. Exogenous estrogen is supplied to induce growth of the explanted tissue. In some cases, the harvested endometrial cells are cultured *in vitro* prior to implantation. Treatment consisting of F-I supplied by gastric lavage on a daily basis for 3-16 weeks, and implants are removed and measured for growth or regression. At the time of sacrifice, the uteri are harvested to assess the status of the intact endometrium.

10 Test 5: Tissue from human endometrial lesions is harvested and maintained *in vitro* as primary non-transformed cultures. Surgical specimens are pushed through a sterile mesh or sieve, or alternately teased apart from surrounding tissue to produce a single cell suspension. Cells are maintained in media containing 10% serum and antibiotic. Rates of growth in the presence and absence of estrogen are determined. Cells are assayed for their ability to produce complement component C3 and their response to growth factors and growth hormone. *In vitro* cultures are assessed for their proliferative response following treatment with progestins, GnRH, F-I, and vehicle. Levels of steroid hormone receptors are assessed weekly to determine whether important cell characteristics are maintained *in vitro*. Tissue from 5-25 patients is utilized.

20

Use of Formula (I) Compound in Conjunction with Estrogen

Peri- and post-menopausal women often undergo hormone replacement therapy (HRT) to combat negative consequences associated with the drop in circulating endogenous estrogen, *e.g.*, to treat hot flashes. However, HRT has been associated with increased risks of certain cancers including uterine and breast cancer. F-I may be employed in conjunction with HRT to inhibit these risks.

Prevention of Breast Cancer

30 This invention also relates to the administration of F-I to a recipient who is at risk of developing *de novo* breast cancer. The term "*de novo*", as used herein, means the lack of transformation or metamorphosis of normal breast cells to cancerous or malignant cells in the first instance. Such a transformation may occur in stages in the same or daughter

cells via an evolutionary process or may occur in a single, pivotal event. This *de novo* process is in contrast to the metastasis, colonization, or spreading of already transformed or malignant cells from the primary tumor site to new locations.

5 A person who is at no particular risk of developing breast cancer is one who may develop *de novo* breast cancer, has no evidence or suspicion of the potential of the disease above normal risk, and who has never had a diagnosis of having the disease. The greatest risk factor contributing to the development of breast carcinoma is a personal history of suffering from the disease, or an earlier occurrence of the disease, even if it is in remission with no evidence of its presence. Another risk factor is family history of the disease.

10 Induction of mammary tumors in rats by administration of the carcinogen N-nitroso-N-methylurea is a well-accepted animal model for the study of breast cancer and has been found suitable for analyzing the effect of chemopreventive agents.

In two separate studies, 55-day old female Sprague-Dawley rats are given an intravenous (Study 1) or intraperitoneal (Study 2) dose of 50 mg of N-nitroso-N-
15 methylurea per kilogram of body weight one week prior to feeding *ad libitum* a diet into which varying amounts of F-I, (Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine base (tamoxifen base), or control are blended.

In Study 1, the dietary doses of 60 mg/kg of diet and 20 mg/kg of diet translates into roughly comparable doses of 3 and 1 mg/kg of body weight for the test animals.

20 In Study 2, the dietary doses of 20, 6, 2, and 0.6 mg/kg of diet translates roughly into comparable doses of 1, 0.3, 0.1 and 0.03 mg/kg of body weight for the test animals.

Rats are observed for evidence of toxicity and are weighed and palpated for tumor formation once a week. The animals are sacrificed after thirteen weeks (Study 1) or eighteen weeks (Study 2) and tumors are confirmed and weighed at autopsy.

25

Therapeutic Methods of Use and Dosages

The present invention also provides a method of inhibiting a disease associated with estrogen deprivation and a method for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen which comprises the
30 aforementioned method using compounds of Formula I and optionally comprises administering to a patient an effective amount of estrogen or progestin. These treatments are particularly useful for treating osteoporosis and lowering serum cholesterol because

the patient will receive the benefits of each pharmaceutical agent while the compounds of the present invention would inhibit undesirable side-effects of estrogen and progestin.

Activity of these combination treatments in any of the post-menopausal tests, *infra*, indicates that the combination treatments are useful for alleviating the symptoms of post-menopausal symptoms in women.

5 Various forms of estrogen and progestin are commercially available. Estrogen-based agents include, for example, ethynyl estrogen (0.01 - 0.03 mg/day), mestranol (0.05 - 0.15 mg/day), and conjugated estrogenic hormones such as Premarin[®] (Wyeth-Ayerst; 0.3 - 2.5 mg/day). Progestin-based agents include, for example, medroxyprogesterone
10 such as Provera[®] (Upjohn; 2.5 -10 mg/day), norethynodrel (1.0 - 10.0 mg/day), and nonethindrone (0.5 - 2.0 mg/day). A preferred estrogen-based compound is Premarin[®], and norethynodrel and norethindrone are preferred progestin-based agents.

The method of administration of each estrogen- and progestin-based agent is consistent with that which is known in the art. For the majority of the methods of the
15 present invention, compounds of Formula I are administered continuously, from 1 to 3 times daily. However, cyclical therapy may especially be useful in the treatment of endometriosis or may be used acutely during painful attacks of the disease. In the case of restenosis, therapy may be limited to short (1-6 months) intervals following medical procedures such as angioplasty.

20 As used herein, the term "patient" refers to a warm-blooded animal or mammal which is in need of inhibiting a disease associated with estrogen deprivation or in need of inhibiting a disease associated with an aberrant physiological response to endogenous estrogen. It is understood that guinea pigs, dogs, cats, rats, mice, hamsters, and primates, including humans, are examples of patients within the scope of the meaning of the term.
25 Preferred patients include humans. Most preferred patients include postmenopausal female humans.

As used herein, the term "inhibit" is defined to include its generally accepted meaning which includes preventing, prohibiting, restraining, and slowing, stopping or reversing progression, or severity, and holding in check and/or treating existing
30 characteristics. The present method includes both medical therapeutic and/or prophylactic treatment, as appropriate.

The term "estrogen deprivation" is meant to imply the condition where the optimal level of estrogen is absent. This level varies from one tissue to another depending on the function of the tissue. Thus, in some cases, estrogen deprivation may be the total absence of estrogen, whereas in other cases, deprivation may involve estrogen levels which are too low for proper tissue function. In human women, the two most common causes of estrogen deprivation are menopause and ovariectomy, although other conditions can be causative. Estrogen deprivation can lead to conditions including osteoporosis and cardiovascular effects such as hyperlipidemia, proliferation of aortal smooth muscle cells (restenosis), decrease in nitric oxide production (hypertension) and decrease in production of the enzyme PAI-1 (Plasminogen Activator Inhibitor-1), i.e. thrombosis.

Reduction or amelioration of other pathologies associated with menopause such as urinary incontinence, vaginal dryness, increase in the incidence of auto-immune disease, and loss of skin tone, may also be achieved by administering compounds of Formula I.

In addition to their usefulness in treating conditions associated with estrogen deprivation following menopause, the compounds of the present invention are also useful in the treatment of disease states associated with inappropriate response to endogenous estrogen in tissues both prior to and subsequent to menopause.

One example of a pathological condition associated with abnormal cellular responses to endogenous estrogen in tissues is estrogen dependent breast cancer. Estrogen dependent breast tumor cells proliferate in the presence of estrogen and the treatment of this disease has been to stop all action of estrogen on these cells.

Another estrogen dependent pathology is uterine fibrosis (uterine fibroid disease). Essentially, uterine fibrosis is a condition where there is a deposition of fibroid tissue on the wall of the uterus. This condition is a cause of dysmenorrhea and infertility in women. The exact cause of this condition is poorly understood but evidence suggests that it is an inappropriate response of fibroid tissue to estrogen. The most common treatment of uterine fibrosis involves surgical procedures both costly and sometimes a source of complications such as the formation of abdominal adhesions and infections.

Yet another disease in this category is endometriosis, a condition of severe dysmenorrhea, which is accompanied by severe pain, bleeding into the endometrial masses or peritoneal cavity and often leads to infertility. The cause of the symptoms of

this condition appear to be ectopic endometrial growths located in inappropriate tissues which respond inappropriately to hormonal control.

As used herein, the term "therapeutically effective amount" means an amount of compound of the present invention which is capable of alleviating the symptoms of the various pathological conditions herein described. The specific dose of a compound administered according to this invention will, of course, be determined by the particular circumstances surrounding the case including, for example, the compound administered, the route of administration, the state of being of the patient, and the pathological condition being treated. A typical daily dose for human use will contain a nontoxic dosage level of from about 1 mg to about 600 mg/day of a compound of the present invention. Preferred daily doses generally will be from about 15 mg to about 300 mg/day. Most preferred doses range may range from 20 mg to about 100 mg, administered once to three times per day.

The compounds of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds preferably are formulated prior to administration, the selection of which will be decided by the attending physician. Thus, another aspect of the present invention is a pharmaceutical composition comprising an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, optionally containing an effective amount of estrogen or progestin, and a pharmaceutically acceptable carrier, diluent, or excipient.

The total active ingredients in such formulations comprises from 0.1% to 99.9% by weight of the formulation. By "pharmaceutically acceptable" it is meant the carrier, diluent, excipients and salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.

Pharmaceutical formulations of the present invention can be prepared by procedures known in the art using well known and readily available ingredients. For example, the compounds of formula I, with or without an estrogen or progestin compound, can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such

as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl-pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols.


The compounds also can be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for example, by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like. The formulations can be so constituted that they release the active ingredient only or preferably in a particular physiological location, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.

Compounds of formula I, alone or in combination with a pharmaceutical agent of the present invention, generally will be administered in a convenient formulation.

-43-

I CLAIM:

1. A compound of the formula



wherein

R^1 is -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), or -OSO₂(C₂-C₆ alkyl);

10 R^0 , R^2 and R^3 are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₂-C₆ alkyl) or halo;

R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

15 n is 2 or 3;

X is -S- or -HC=CH-; and


Y is -O-, -S-, -NH-, -NMe-, or -CH₂-;

or a pharmaceutically acceptable salt thereof.

20

-44-

2. A compound of Claim 1 of the formula



wherein

- 5 R^1 is -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), or -OSO₂(C₂-C₆ alkyl);
- R^2 and R^3 are each independently -H, -OH, -O(C₁-C₄ alkyl), -OCOC₆H₅, -OCO(C₁-C₆ alkyl), -OSO₂(C₂-C₆ alkyl) or halo;
- R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;
- n is 2 or 3;
- X is -S- or -HC=CH-; and
- Y is -O-, -S-, -NH-, -NMe-, or -CH₂-;
- 15 or a pharmaceutically acceptable salt thereof.

3. A compound according to Claims 1 or 2 wherein Y is -O-.

4. A compound according to any of Claims 1 to 3 wherein n is 2.

20

5. A compound according to any of Claims 1 to 4 wherein R^1 is -OH or -OCH₃.

6. A compound according to any of Claims 1 to 5 wherein R^1 is -OH.

25

7. A compound according to any of Claims 1 to 6 wherein R^4 is 1-piperidinyl or 1-pyrrolidinyl.

8. A compound according to any of Claims 1 to 7 wherein R⁴ is 1-piperidinyl.
9. A compound according to any of Claims 1 to 8 wherein two of R⁰, R² and
5 R³ are -H.
10. A compound according to any of Claims 1 to 8 wherein two of R⁰, R² and
R³ are -H and the other is -OH.
- 10 11. A compound according to any of Claims 1 to 9 wherein R⁰, R² and R³ are
all -H.
12. A compound according to any of Claims 1 to 11 wherein X is -S-.
- 15 13. A compound according to any of Claims 1 to 12 wherein X is -HC=CH-.
14. A compound according to Claim 1 wherein said compound is selected
from the group consisting of:
- 11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-
20 d]thiophen-3-ol;
- 11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-
d]thiophene-3,8-diol;
- 11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-
d]thiophene-3,10-diol;
- 25 11-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-6,11-dihydro-benzo[b]naphtho[2,3-
d]thiophene-3,9-diol;
- 10-Fluoro-12-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-
benzo[a]anthracen-3-ol;
- 12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,10-
30 diol;
- 12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,9-
diol;

12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,11-diol;

12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,8-diol;

5 or a pharmaceutically acceptable salt thereof.

15. A compound according to Claim 1 wherein said compound is 12-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-7,12-dihydro-benzo[a]anthracene-3,9-diol or a pharmaceutically acceptable salt thereof.

10

16. A pharmaceutical composition comprising a compound according to any of Claims 1 to 15 or a pharmaceutically acceptable salt thereof, and optionally an effective amount of estrogen and progestin, in combination with a pharmaceutically acceptable salt, diluent, or excipient.

15

17. A method for inhibiting a disease associated with estrogen deprivation comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of Claims 1 through 15.

20

18. A method according to Claim 17 wherein said patient is a human.

19. A method according to Claim 18 wherein said patient is a postmenopausal female.

25

20. A method according to any of Claims 17 to 19 wherein said disease is bone loss.

21. A method according to any of Claims 17 through 19 wherein said disease is cardiovascular disease.

30

22. A method for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen comprising administering to a patient in need thereof a

therapeutically effective amount of a compound according to any one of Claims 1 through 15.

23. A method according to Claim 22 wherein said patient is a human.

5

24. A method according to Claim 23 wherein said patient is a postmenopausal female.

25. A method according to any of Claims 22 through 24 wherein the disease associated with an aberrant physiological response to endogenous estrogen is estrogen dependent cancer.

10

26. A method according to Claim 25 wherein said cancer is breast cancer.


27. A method according to any of Claims 22 through 24 wherein the disease associated with an aberrant physiological response to endogenous estrogen is endometriosis.

15

28. A method according to any of Claims 22 through 24 wherein the disease associated with an aberrant physiological response to endogenous estrogen is uterine fibrosis.

20

29. A compound of the formula



25

wherein

R^{1a} is $-H$ or $-Opg$, wherein Pg is a hydroxy protecting group;

-48-

R^{0a} , R^{2a} , and R^{3a} are independently R^{1a} or halo;

R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;


5 n is 2 or 3; and

Y is $-O-$, $-S-$, $-NH-$, $-NMe-$, or $-CH_2-$;

or a pharmaceutically acceptable salt thereof.

30. A compound according to Claim 29 wherein said compound is (2-benzyl-6-methoxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; or a pharmaceutically acceptable salt thereof.

31. A compound of the formula



15

wherein

R^{1a} is $-H$ or $-Opg$, wherein Pg is a hydroxy protecting group;

R^{0a} , R^{2a} , and R^{3a} are independently R^{1a} or halo;

20 R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3; and


Y is $-O-$, $-S-$, $-NH-$, $-NMe-$, or $-CH_2-$;

or a pharmaceutically acceptable salt thereof.

25

32. A compound according to Claim 31 wherein said compound is (2-benzyl-6-methoxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanol; or a pharmaceutically acceptable salt thereof.

5 33. A compound of the formula



wherein

R^{1a} is -H or -Opg, wherein Pg is a hydroxy protecting group;

10 R^{0a} , R^{2a} , and R^{3a} are independently R^{1a} or halo;

R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3; and

15 Y is -O-, -S-, -NH-, -NMe-, or -CH₂-;


or a pharmaceutically acceptable salt thereof.

34. A compound according to Claim 33 wherein said compound is [2-(4-fluoro-benzyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; or a pharmaceutically acceptable salt thereof.

20

35. A compound of the formula

-50-



(10)

wherein

R^{1a} is -H or -Opg, wherein Pg is a hydroxy protecting group;

R^{0a} , R^{2a} , and R^{3a} are independently R^{1a} or halo;

5 R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3; and

Y is -O-, -S-, -NH-, -NMe-, or -CH₂-;

10 or a pharmaceutically acceptable salt thereof.

36. A compound according to Claim 35 wherein said compound is [2-(4-fluoro-benzyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanol; or a pharmaceutically acceptable salt thereof.

15

37. The use of a compound according to any of Claims 1 to 15 for the manufacture of a medicament.

38. The use of a compound according to any of Claims 1 to 15 for the
20 manufacture of a medicament for inhibiting a disease associated with estrogen deprivation.

39. The use according to Claim 38 wherein said disease is bone loss.

25 40. The use according to Claim 38 wherein said disease is cardiovascular disease.

41. The use of a compound according to any of Claims 1 to 15 for the manufacture of a medicament for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.

5 42. The use according to Claim 41 wherein said disease is estrogen dependent cancer.

43. The use according to Claim 42 wherein said cancer is breast cancer.

10 44. The use according to Claim 41 wherein the disease associated with an aberrant physiological response to endogenous estrogen is endometriosis.

45. The use according to Claim 41 wherein the disease associated with aberrant physiological response to endogenous estrogen is uterine fibrosis.

15

46. A pharmaceutical composition for inhibiting a disease associated with deprivation containing as an active ingredient a compound according to Claims 1 to 15.

20 47. A pharmaceutical composition for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen containing as an active ingredient a compound according to any of Claims 1 to 15.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/26304

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D409/12 C07D295/08 A61K31/381 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GRESE T A ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS OF SELECTIVE ESTROGEN RECEPTOR MODULATORS: MODIFICATIONS TO THE 2-ARYLBENZOTHIOPHENE CORE OF RALOXIFENE" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 2, 17 January 1997 (1997-01-17), pages 146-167, XP002050782 ISSN: 0022-2623 page 152; table 3 compound 131	29
X	EP 0 759 434 A (LILLY CO ELI) 26 February 1997 (1997-02-26) examples 10,11 claim 1	29-32

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed
- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search 13 January 2004	Date of mailing of the international search report 05/02/2004
---	---

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Samsam Bakhtiary, M
--	--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/26304

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 761 669 A (LILLY CO ELI) 12 March 1997 (1997-03-12) page 3, line 3-8 claim 1 -----	1-47
A	WO 02 16316 A (MESTRES JORDI ;AKZO NOBEL NV (NL); LOOZEN HUBERT JANJOZEF (NL); VE) 28 February 2002 (2002-02-28) page 1, line 4-9 claim 1 -----	1-47

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 17-28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 03/26304

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210

2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 03/26304

Patent document cited in search report		Publication date	Patent family member(s)	Publication date			
EP 0759434	A	26-02-1997	AU 6774096 A	12-03-1997			
			CA 2228997 A1	27-02-1997			
			EP 0759434 A1	26-02-1997			
			JP 11511169 T	28-09-1999			
			WO 9706796 A1	27-02-1997			
			US 5728724 A	17-03-1998			

EP 0761669	A	12-03-1997	AT 197712 T	15-12-2000			
			AU 705454 B2	20-05-1999			
			AU 6959096 A	27-03-1997			
			BR 9610356 A	06-07-1999			
			CA 2230974 A1	13-03-1997			
			CN 1201392 A	09-12-1998			
			CZ 9800678 A3	17-06-1998			
			DE 69611015 D1	28-12-2000			
			DE 69611015 T2	10-05-2001			
			DK 761669 T3	11-12-2000			
			EA 1649 B1	25-06-2001			
			EP 0761669 A2	12-03-1997			
			ES 2152496 T3	01-02-2001			
			GR 3035253 T3	30-04-2001			
			HU 9802213 A2	01-02-1999			
			IL 123560 A	10-02-2002			
			IL 140162 A	10-02-2002			
			JP 11514347 T	07-12-1999			
			NO 980936 A	07-05-1998			
			NZ 318183 A	24-09-1998			
			PL 325479 A1	20-07-1998			
			PT 761669 T	30-04-2001			
			SI 761669 T1	30-04-2001			
			TR 9800387 T1	21-05-1998			
			WO 9709044 A1	13-03-1997			
			US 6133288 A	17-10-2000			
			US 5726186 A	10-03-1998			
			US 6004971 A	21-12-1999			

			WO 0216316	A	28-02-2002	AU 8210101 A	04-03-2002
BR 0113444 A	24-06-2003						
CA 2420289 A1	28-02-2002						
CN 1447791 T	08-10-2003						
CZ 20030514 A3	15-10-2003						
WO 0216316 A1	28-02-2002						
EP 1313700 A1	28-05-2003						
NO 20030759 A	15-04-2003						
SK 2052003 A3	01-07-2003						
